Management of Women With BRCA1/2 Mutation

Role of General Practionners in Management of Women With BRCA1/2 Mutation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03211611

Enrollment

600

Registered

2017-07-07

Start date

2017-04-01

Completion date

2017-11-01

Last updated

2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA1 Mutation, BRCA2 Mutation

Keywords

BRCA1/2 Mutation, Breast cancer, General practitionner

Brief summary

The aim of this study is to determine general practitionners' role in management of women with BRCA1/2 mutation. This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women followed-up in the department of genetics and their general practitionners (GP). Patients and their GP will be called by the investigators and questionnaire will be given to them. Questionnaire includes questions for patients and their GP. The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 / 2 mutation. Adequate knowledge includes : systematic search for a family history of cancer, knowing criteria required to refer women in oncogenetic department, and the ability to respond to patients' questions. Secondary endpoint was to determine women' opinion on their GP : whether or not well managed for their BRCA 1 / 2 mutation.

Detailed description

PURPOSE: The aim of this study is to determine general practitionners' role in management of women with BRCA1/2 mutation. METHODS: This study will be conduct between April 2017 and December 2017 at Montpellier University Hospital on women followed-up in the department of genetics and their general practitionners (GP). Patients and their GP will be called by the investigators and questionnaire will be given to them. Questionnaire includes questions for patients and their GP. The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 / 2 mutation. Adequate knowledge includes : systematic search for a family history of cancer, knowing criteria required to refer women in oncogenetic department, and the ability to respond to patients' questions. Secondary endpoint was to determine women' opinion on their GP : whether or not well managed for their BRCA 1 / 2 mutation.

Interventions

BEHAVIORALQuestionnaire given to the two groups

Questionnaire given to the two groups : Patients with BRCA ½ mutation GP

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged over 18 * Women * Living in France * Having a medical insurance

Exclusion criteria

* Men * Dementia * Non frenchspeaker * Mental retardation * Being the subject of a guardianship or tutelage measure

Design outcomes

Primary

Measure	Time frame	Description
The rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 / 2 mutation.	1 day	Adequate knowledge includes : systematic search for a family history of cancer, knowing criteria required to refer women in oncogenetic department, and the ability to respond to patients' questions

Secondary

Measure	Time frame	Description
Women' opinion on their GP	1 day	Women' opinion on their GP : whether or not well managed for their BRCA 1 / 2 mutation. The rate of GP wanting a formation in oncogenetic

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026